Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

New data for Halaven® (eribulin), Lenvima® (lenvatinib) and Kisplyx® (lenvatinib) demonstrate continued strength of Eisai oncology portfolio at ESMO 2016

Eisai
Posted on: 30 Sep 16

Hatfield, UK, 28 September 2016 – Eisai highlights nine new data abstracts in hard to treat cancers
for eribulin and lenvatinib at the European Society for Medical Oncology (ESMO) Congress, Copenhagen, 7-11 October 2016.

 

Lenvatinib data in thyroid cancer, renal cell carcinoma and other solid tumours

An investigational phase II study for lenvatinib focuses on the treatment of KIF5B-RET–positive adenocarcinoma of the lung.[i] Adenocarcinoma is a type of non-small cell lung carcinoma, one of the most common forms of lung cancer.1 RET fusions activate RET kinase and occur in 1-2% of patients.1

 

Exploratory early phase data will review lenvatinib with anti PD-1 therapy including a phase Ib/II study in people with selected solid tumours.[ii]

 

Subanalyses from the pivotal SELECT study investigate responses in specific metastasis sites following treatment with lenvatinib for patients with radioiodine-refractory (RAI-R) differentiated thyroid cancer (DTC).[iii] SELECT is a multicentre randomised, double-blind, placebo-controlled phase III study to compare the progression-free survival (PFS) of patients with radioiodine-refractory differentiated thyroid cancer.[iv]

 

A pre-clinical study examines the VEGFR and FGFR signalling pathway participation in tumour growth and angiogenesis in human renal cell carcinoma xenografts treated with the combination of lenvatinib plus everolimus.[v] A further pre-clinical study analyses immune response in syngeneic murine tumour models to understand the antitumour effect and mechanism of action of the combination of lenvatinib and PD-1 blockade treatment in a number of cancer models.[vi]

 

Epidemiological data in metastatic breast cancer

This study investigates the progressive decline in efficacy of active agents in locally advanced
or metastatic breast cancer with each successive therapy cycle.[vii] The study includes data from 443 patients in Spain with locally advanced or metastatic breast cancer.7

 

Eribulin data in metastatic breast cancer

A study investigates the safety of eribulin in third-line chemotherapy in 59 patients with HER2-negative metastatic or locally advanced breast cancer.[viii] 

 

Exploratory data from the investigational, phase II, multicenter, single arm trial (MERIBEL) will examine the efficacy and safety of eribulin as a first-line therapy for HER2- metastatic breast cancer.[ix]

 

Eribulin data in soft tissue sarcomas

Results will be presented from a pre-specified subgroup analysis in leiomyosarcomas of the phase III 309 study comparing eribulin to dacarbazine.[x] Eribulin is not licensed in leiomyosarcomas in the European Union.

“Eisai is committed to the development of innovative treatments for people with cancer and always gives first thought to patients and their families. Eribulin has demonstrated a unique overall survival benefit compared to active comparators in advanced or metastatic breast cancer and unresectable liposarcoma. Lenvatinib delivers rapid, pronounced and durable responses; and significantly prolongs the time before a cancer progresses in both advanced thyroid and advanced kidney cancer," comments Gary Hendler, Chairman & CEO EMEA and Chief Commercial Officer, Global Oncology Business Group.

 

Product

Abstract Name

Presentation Details

Lenvatinib

Poster: 1204PD

Phase 2 study of lenvatinib in patients with RET
fusion–positive adenocarcinoma of the lung

Velcheti V et al

 

Poster Discussion:

NSCLC, metastatic

Date: 09 Oct 16

Time: 14:45-16:15

Room: Oslo

Lenvatinib

Poster: 776PD

A phase 1b trial of lenvatinib plus pembrolizumab in patients with selected solid tumours

Taylor M et al

Poster Discussion:

Genitourinary tumours, non-prostate

Date: 09 Oct 16

Time: 16:30-17:30

Room: Athens

Lenvatinib

Poster: 2PD

Lenvatinib mesylate enhanced antitumour activity of PD-1 blockade agent by potentiating Th1 immune response

Kato Y et al

Poster Discussion:

Basic science and translational research

Date: 09 Oct 16

Time: 16:30-17:30

Room: Berlin

Lenvatinib

Poster: 962P

Responses in specific metastases following treatment with lenvatinib: results from the phase 3 SELECT study

Robinson B et al

Poster Presentation:

Poster display

Date: 09 Oct 16

Time: 13:00-14:00

Room: Hall E

Lenvatinib

Poster: 6P

The antitumour activity of lenvatinib in combination with everolimus in human RCC xenograft models is dependent on VEGFR and FGFR signalling

Kimura T et al

Poster Presentation:

Poster display

Date: 10 Oct 16

Time: 13:00-14:00

Room: Hall E

Epidemiological Data

Poster: 248P

CASCADE study: pronounced decline in treatment efficacy through the metastatic life of breast cancer patients

De Paz L et al

 

Poster Presentation:

Poster display

Date: 10 Oct 16

Time: 13:00-14:00

Room: Hall E

Eribulin

Poster: 238P

MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients

Ortega V et al

Poster Presentation:

Poster display

Date: 10 Oct 16

Time: 13:00-14:00

Room: Hall E

Eribulin

Poster: 246P

Single arm, multicentre, non-randomized open-label trial to evaluate the safety of eribulin in third line chemotherapy in patients with HER2-negative metastatic or locally advanced breast cancer previously treated with anthracyclines and taxanes: Onsite study (ONCOSUR 2012-02)

Sanchez L et al

Poster Presentation:

Poster display

Date: 10 Oct 16

Time: 13:00-14:00

Room: Hall E

Eribulin

Poster: 1401PD

Subgroup analysis in leiomyosarcoma (LMS) patients from a phase 3, open-label, randomised study of eribulin versus dacarbazine in patients with advanced liposarcoma (LPS) and LMS

Blay J et al

Poster Discussion:

Sarcoma

Date: 10 Oct 16

Time: 11:00-12:00

Room: Brussels

 

 

 

Eisai in Oncology

Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, and biologic and supportive care agents for cancer across multiple indications.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 30/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.